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Abstract
Huntington disease (HD) is a late onset ultimately fatal neurodegenerative disorder caused by a 
CAG triplet repeat expansion in the Huntingtin gene which was discovered in 1993. The PHAROS 
study is a unique observational study of 1001 individuals at risk for HD who had not been 
previously tested for HD and who had no plans to do so. In this cohort, 104 (10%) individuals 
changed their minds and chose to be tested during the course of the study but outside of the study 
protocol.
Baseline behavioral scores, especially apathy, were more strongly associated with later genetic 
testing than motor and chorea scores, particularly among subjects with expanded CAG repeat 
length. In the CAG expanded group, those choosing to be tested were older and had more chorea 
and higher scores on the behavioral section of the UHDRS at baseline than those not choosing to 
be tested. Following genetic testing, 56% of subjects with CAG < 37 had less depression when 
compared to prior to testing, but depression generally stayed the same or increased for 64% of 
subjects in the expanded group. This finding suggests that approaches to testing must continue to 
be cautious, with appropriate medical, psychological and social support.
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Introduction
Huntington disease (HD) is a relatively rare, highly penetrant, inherited neurodegenerative 
disorder with a prevalence of 4.1 – 7.5 cases per 100,000 in the Caucasian population (1). 
The characteristic signs of HD include abnormal movements, cognitive decline often leading 
to dementia, and a variety of psychiatric disorders, most notably depression. These clinical 
features gradually emerge around the age of 40, although the onset of the disease has been 
seen in children as young as 2 and adults as old as 70 (2). Death normally occurs between 
ten and seventeen years after onset (3). It is estimated that some 30,000 individuals in the 
United States and Canada have clinically manifest HD, and an additional 150,000 are at 
50:50 risk of having inherited a mutated HTT gene (4, 5).
HD is inherited in an autosomal dominant pattern such that each child of an affected parent 
has a 50:50 chance of having inherited the HD gene; men and women are equally likely to 
be affected. In 1983, genetic markers linked to the HD gene were first identified, allowing 
some individuals at risk, if their family structure permitted, to establish whether or not they 
would develop HD using a process known as linkage analysis (6). In 1986, centers at 
Massachusetts General Hospital in Boston and The Johns Hopkins Hospital in Baltimore 
began offering pre-symptomatic testing for HD on an experimental basis. Testing protocols 
included psychiatric screening, a neurological examination, mandatory counseling, informed 
consent, results given in person and long term follow-up and excluded testing individuals 
under the age of 18 years. Preliminary findings began to appear in the literature suggesting 
that testing for HD could be done safely when administered in the context of these structured 
research protocols (7, 8, 9).
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In 1993, the underlying genetic cause of HD was discovered to be a cytosine-adenine-
guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene on chromosome 
4 (Huntington Disease Collaborative Research Group, 1993). This discovery meant that the 
presence or absence of the HD gene mutation could be determined in any at-risk individual 
by direct gene testing for the expanded CAG repeat, without regard to the participation of 
other family members. Studies done prior to the finding of the HD mutation suggested that 
there would be high rates of utilization for predictive testing in individuals at risk for HD 
(10, 11, 12, 13, 14). However, current estimates indicate that only 12-15% of adults at risk 
have elected to pursue so-called pre-symptomatic testing (15, 16), although a recent report 
suggests that uptake may be increasing in some countries (17).
Most of the information we have about individuals who have undergone pre-symptomatic 
testing for the mutated HTT gene comes from the test centers themselves which, by 
necessity, can only collect data from individuals who present for testing (7, 15, 17,18, 19, 
20, 21, 22, 23). Previous studies indicate that the majority of those choosing to be tested are 
women, with percentages ranging from 57.6% to 66.7% (24, 4, 25, 26, 22, 17, 23). The 
mean age of adults requesting testing may be trending lower with time, from a high of 40.5 
(26) to 36.4 (22) to 30 (17). Few differences in psychological outcomes between those who 
received a positive result (expanded CAG repeat) compared to a negative result (non-
expanded CAG repeat) have been reported (27) and most appear to be related more to 
psychological adjustment prior to testing than the test result itself. Although the duration of 
follow up differs, ranging from 3 to 10 years, no direct catastrophic outcomes have been 
reported as a consequence of pre-symptomatic testing for the HD gene.
While generally concurring with the long term effects of testing, Hayden and Bombard (28) 
examined the psychosocial effects of testing and focused primarily on the 5-10% of people 
who enter predictive testing programs already manifesting signs and symptoms of this 
disease. They report that their clinical experience suggests that, at least in the short term, 
these candidates who receive results indicating an increased risk undergo a difficult period of 
adjustment with some experiencing a prolonged period of considerable emotional distress 
(29). Factors associated with a difficult adjustment include a past history of psychiatric 
disorder and adverse responses to other difficult life events such as the loss of a spouse or 
change in employment status.
In preparation for future clinical trials, the Huntington Study Group, a consortium of HD 
researchers, conducted a study of individuals at risk for HD. This study, the Prospective 
Huntington At-Risk Observational Study (PHAROS), was designed to establish whether 
experienced clinicians can reliably identify emerging clinical signs and symptoms that 
indicate the earliest onset of HD in clinically unaffected individuals at risk for carrying the 
HD gene who have chosen not to undergo pre-symptomatic genetic testing. The PHAROS 
study, therefore, presents a unique research setting to examine factors related to the 
decisions by at-risk research participants who had at enrollment chosen not to pursue genetic 
testing and had indicated no plans to do so in the future but who subsequently changed their 
mind about testing (30).
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The purpose of this report is to examine the factors associated with the decision to be tested 
by PHAROS research participants who changed their minds and opted to undergo pre-
symptomatic HD genetic testing, compared with those who still chose not to be tested.
Materials and Methods
Between July 1999 and January 2004, 1001 clinically unaffected adults at risk for HD who 
had chosen not to undergo predictive genetic testing for the presence or absence of the 
mutated HTTgene were enrolled in this non-interventional, observational, longitudinal study. 
Study visits included the Unified Huntington's Disease Rating Scale (UHDRS) (31); the 
Beck Depression Inventory (32); medical history; surveys of attitudes, perceptions, and 
beliefs regarding HD; neuropsychological testing; and a one-time research analysis at 
enrollment for the HD CAG expansion. A central basis of consent was that individual and 
potentially identifiable results of CAG analysis would never be disclosed to anyone, neither 
investigators, clinicians, research participants nor their families. Participants returned for 
research visits about every nine months and committed to at least three years of observation, 
a period that was subsequently extended for an additional 7 years through consent 
amendments. All sites received institutional review board approval of the protocols and 
consent procedures.
Genotype Assessment
Coded venous blood samples from research participants were sent to the DNA laboratory of 
the Molecular Neurogenetics Unit at Massachusetts General Hospital where CAG repeat 
analysis was performed under the direction of Marcy MacDonald, PhD, using previously 
described techniques (33). A bar code system de-identified the samples, thereby preventing 
anyone from gaining access to or linking individually identifiable genetic and clinical data. 
All participants and site personnel were blinded to the results.
Clinical Assessment
At the initial evaluation, a site coordinator and site investigator (SI) obtained a 
comprehensive medical history and physical examination, including the UHDRS. An 
independent rater (IR) at each site served strictly as a motor examiner, interacting with 
research participants only to assess the motor component of the UHDRS. A key item on the 
motor examination requires the rater to assign a level of ‘diagnostic confidence of HD’. A 
rating of 4, motor abnormalities that are unequivocal signs of HD with ≥ 99% confidence 
(phenoconversion), has been found to have good reliability among independent raters (34). 
The UHDRS behavioral assessment consists of eleven items (depressed mood, low self-
esteem/guilt, anxiety, suicidal thoughts, disruptive or aggressive behavior, irritable behavior, 
perseverative/obsessional thinking, compulsive behavior, delusions, hallucinations, apathy), 
each of which is evaluated for frequency and severity on scales of 0 (never or almost never/
none) to 4 (very frequently/severe); a total behavioral score was calculated as frequency 
times severity, summed over the eleven items, and individual questions were coded as 
impaired if either frequency or severity was ≥ 2. The cognitive portion of the UHDRS 
includes a test of category fluency (number of words beginning with a specified letter), the 
symbol digit modalities test (pairing of symbols and numbers), and the Stroop interference 
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test (identification of words and colors), with lower scores indicating worse impairment. The 
functional portion includes total functional capacity (TFC), which measures the subject's 
overall functioning in the areas of employment, finances, domestic chores, activities of daily 
living, and need for care. The UHDRS includes a question asking if the participant since the 
last visit had obtained HD gene testing outside of the research protocol.
The Life Experiences Survey is a 57-item, self-report measure that allows respondents to 
indicate life events that they have experienced in the last year. Participants rate the impact of 
each event, and the numbers of negative and positive events can be calculated (35).
Statistical Methods
Subject characteristics were compared by genetic testing status using Kruskal-Wallis tests or 
chi-square tests, as appropriate. Pre-specified potential predictors of time to genetic testing 
were evaluated using separate Cox proportional hazards models, adjusted for age and 
gender, and then creating a combined model that included only those measures that were 
significant in individual models. Similar Cox proportional hazards models were also used to 
evaluate the UHDRS functional and cognitive scores and the individual items on the 
UHDRS behavioral score. Among subjects who had changed their minds and decided to be 
tested, scores were compared by CAG status at the visit immediately prior to and at the one 
where the testing was reported using Kruskal-Wallis tests, and changes between these two 
visits were assessed using analysis of covariance on the ranks, with scores from the prior 
visit included in the models. The same method was also used to evaluate depression at the 
two visits following the one where testing was reported.
A case-control subset was used to compare participants who opted to undergo genetic testing 
with those who did not, at the visit prior to the one where the testing was reported. 
Participants who had obtained genetic testing outside of the study were matched with 
participants who were never tested based on four factors: visit number when genetic testing 
was first reported, prior visit number, gender, and CAG repeat length (<37 vs ≥37), three 
controls to one case. Conditional logistic regression was used to assess the effects of pre-
specified predictors on the decision to obtain testing before the next visit.
Using the case-control cohort and Kruskal-Wallis tests, numbers of negative and of positive 
life events experienced in the year that subjects obtained genetic testing were compared with 
those of matched subjects at the same visit who were not tested, separately by CAG status.
Results
Out of the original study cohort of 1001 unaffected adults at risk for inheriting the HD gene, 
104 (10%) opted to obtain genetic testing outside of the PHAROS research study. While the 
overall cohort consisted of approximately 1/3 CAG expanded and 2/3 CAG non-expanded 
individuals, close to what would be predicted (28), half of those who opted for testing had an 
expanded CAG repeat length (≥ 37) and half did not. The mean time to testing from study 
baseline was 4.3 (2.4) years, with a range of 1 to 10 years.
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For these analyses, four participants lacking CAG data and 14 who had manifested signs of 
HD at study baseline were excluded (28), creating an analysis cohort of N=983 (Figure 1). 
Subject baseline characteristics for this cohort are shown in Table 1. The median age was 
42.1 years; 69% were women and 35% had an expanded CAG repeat. During the study, 101 
(10%) participants in this cohort chose to undergo HD gene testing outside of the study 
protocol. Fifty-one (8%) participants with non-expanded CAG repeat length were tested, 
compared with 50 (14%) participants in the expanded group (p=0.0014, chi-square test). 
Among the 101 participants tested, 73 (72%) were women, 65 (70%) were married, and the 
mean (SD) age at testing was 47.3 (7.5) years.
Compared with the 882 participants who were not tested, those tested did not differ 
significantly by age at the study baseline, gender, or marital status. Participants were not 
significantly different by testing status on the UHDRS motor or Beck depression scores at 
baseline, but those who were later tested scored significantly higher (more impaired) on the 
baseline UHDRS behavioral score (p=0.013, Kruskal-Wallis test) than those who were never 
tested. Among participants with CAG < 37, there were no significant differences at baseline 
between those who were later tested and those who were not tested. However, among 
participants with CAG ≥ 37, those later tested were significantly older (p=0.0048) and had 
significantly more severe chorea scores (p=0.0318) and behavioral scores (p=0.0307) than 
those who were not tested (Table S1).
Individual Cox proportional hazards models revealed that CAG status and the behavioral 
score were significant predictors of time to genetic testing, and both retained significance in 
a combined model (Table 2). When these models were run separately by CAG status, the 
behavioral score was a significant predictor only in the CAG expanded group (p=0.0222) 
(Table S2).
Responses to individual questions on the UHDRS behavioral score showed that participants 
subsequently tested were significantly more likely than those not tested to have low esteem, 
increased irritability, and more apathy at baseline. In an adjusted analysis, apathy was a 
particularly strong predictor in the expanded group (p=0.0004) with 30% of subjects with 
baseline apathy obtaining testing, compared to 11% of subjects who were not apathetic at 
baseline (Table S3). In a Cox model to predict time to testing, adjusted for age, gender and 
CAG status, apathy remained a significant predictor of time to testing (p=0.0258) (data not 
shown).
Among the UHDRS functional and cognitive scores, total functional capacity and the 
symbol digit modalities test were significant in separate models; the symbol digit modalities 
score remained significant (p=0.0098) in a combined model that included age, gender, CAG 
status and the UHDRS behavioral score (data not shown).
Eighty-seven of the 101 tested subjects had scores from the visit immediately prior to the 
visit at which the testing status was made known to the investigator. Scores for these subjects 
at the prior visit were compared by CAG status with those at the testing disclosure visit 
(Table 3). At both the visit prior to testing and the testing disclosure visit, the Beck 
depression scores were not significantly different between the two CAG status groups. 
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However, after testing, among those in the CAG non-expanded group, more than half (56%) 
had less depression than before testing while levels of depression stayed the same or 
increased in 44% of subjects. In the CAG expanded group, 36% had less depression, and 
64% had the same or increased levels of depression following testing (p=0.07). Among 
tested subjects in the CAG expanded group, depression scores appeared to increase at 
subsequent visits following testing, while scores remained lowered in the CAG non-
expanded group (Figure 2). Compared with the CAG non-expanded group, behavior scores 
were higher in the CAG expanded group both before (p=0.07) and after (p=0.0379) testing. 
However, the changes were similar in the two groups (p=0.31).
Analyses to predict genetic testing at the next visit utilized the case-control cohort, and the 
results from separate conditional logistic regression models are shown in Table 4. In a 
combined model, both higher motor scores and higher Beck depression scores were 
marginally significant predictors of opting for testing before the next visit, compared with 
never-tested participants (p=0.07 and p=0.06, respectively).
In similar analyses by CAG status, higher Beck depression scores were the only significant 
predictor of testing before the next visit for subjects with CAG less than 37, whereas higher 
depression, motor and chorea scores were all significant predictors for CAG ≥ 37 subjects 
(Table S4).
Among subjects in the case-control cohort, numbers of negative and numbers of positive life 
events reported at the visit at which the testing was disclosed were not significantly different 
when compared with matched subjects at the same visit who had not been tested. We also 
looked at life events among tested subjects at the visit at which testing was disclosed and the 
first and second follow-up visits and there were no significant differences in positive or 
negative life events for those with CAG expanded test results and those without.
Discussion
Most information about individuals who obtain genetic testing comes from testing centers, 
which obtain data only from those who present for testing. The PHAROS study is unique in 
having the ability to compare participants who obtain genetic testing with those who do not 
in a cohort that was followed longitudinally over several years and whose CAG status was 
concealed from participants and investigators.
As in most studies of at-risk individuals undergoing testing, the majority of those choosing 
to be tested were women (72%). Although there has been speculation about why women 
choose to be tested at a greater rate compared with men, few studies have examined this in 
detail and we know little about why this is so.
Although at enrollment participants in the PHAROS study did not intend to undergo genetic 
testing for the HD gene, 10% subsequently changed their minds and obtained testing 
independent of the study, in keeping with the relatively low uptake of testing reported in 
clinical practice and in other studies. This suggests that decision-making about genetic 
testing is fluid, can change over time, and is likely to be different for different people. There 
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also may be subtle changes in their cognition or mood that are causing such individuals to 
re-consider testing.
In this cohort of individuals who expressly did not desire genetic testing at the time of their 
entry into the study, 101 individuals decided subsequently to be tested outside of the study 
protocol. Their changed decision to be tested may be based on a growing awareness of 
emerging symptoms that may be related to disease onset as evidenced by the fact that those 
in the CAG expanded group had both higher chorea scores and higher behavioral scores, 
specifically higher scores on low self-esteem, increased irritability and apathy. Alternatively, 
for the CAG non-expanded group, the decision to be tested might be based on a growing 
awareness that symptoms are not developing and the wish to eliminate uncertainty.
Although the actual number of individuals choosing to be tested is almost identical, it is 
important to note that a greater percentage of CAG-expanded individuals chose to be tested 
50 (14%) vs in the non-expanded group 51 (8%). In addition, among CAG expanded 
individuals who were tested, 19 (38%) developed manifest signs of HD during the study, 
compared with 42 (14%) of CAG expanded individuals who were not tested. However, our 
analyses have demonstrated that worsening motor and chorea scores did not appear to be the 
sole motivation for testing. Instead, depression, cognitive impairment, and behavioral scores 
(particularly apathy) seemed to be motivating factors. As apathy is considered one of the 
symptoms of HD that is most distressing to caregivers, it is interesting to speculate on what 
role pressure from family members to be tested may have played (36) This finding also 
suggests that for those with an expanded CAG, their decision to be tested may be based on a 
gradual realization of emerging symptoms, a realization that may have been brought to their 
attention by the fact that they were having a neurological examination approximately every 9 
months as a condition of study participation. While this is not a situation at all similar to that 
of most people coming for testing, one may surmise that a certain percentage of the 
population at risk will chose to be tested because they feel that they are becoming 
symptomatic. If so, a neurological examination prior to testing remains an important part of 
the testing process. In addition, HD researchers need to be aware of this possibility as they 
consider entering gene positive individuals into clinical trials in which regular neurological 
examinations are required as a part of the study protocol.
Post-testing measures showed that while depression was not increased for the CAG 
expanded group immediately after testing, over time, depression increased in those who 
learned that they had an expanded CAG repeat, whereas subjects in the non-expanded group 
became less depressed. This finding is in contrast with most published studies showing an 
increase in depression immediately after testing for those with an expanded CAG repeat with 
a return to baseline levels within 1-6 months (36) but is consistent with outcomes found in 
other studies focusing on individuals who come for testing and are exhibiting symptoms 
suggesting that this group may be especially vulnerable should their test indicate an 
expanded CAG repeat. Although the data are limited, it appeared that genetic testing did not 
affect subsequent life experiences in the short term.
This research cohort may differ in some ways from individuals who are not research 
participants and choose gene testing at clinical sites. They are well educated with most 
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having at least some college. They are clearly engaged in HD research, agreeing to return for 
study visits every nine months for several years. And, as a neurological examination was an 
integral part of the study visit, they were forced to be more mindful of emerging symptoms.
In summary, in PHAROS, for those who subsequently opted for testing, this decision 
appears to be motivated by changes in mood, most notably depression, subtle changes in 
cognitive function, and apathy. The fact that depression increased post testing in those with 
expanded CAG repeats, supports a continuing cautious approach to testing, requiring 
appropriate medical, psychological and social support. In addition, the fact that those who 
had an expanded CAG repeat had higher chorea scores also suggests that a neurological 
examination remains an important part of the pre-symptomatic HD testing protocol.
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Figure 1. 
Flow diagram of ascertainment of study cohort.
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Figure 2. Mean (SE) Beck Depression Score Before and After the Visit at Which Testing Was 
Disclosed (N = 61)
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Table 1
Baseline Characteristics by Genetic Testing Status (N = 983)
Never Tested (N = 882) Tested Later (N = 101) All (N = 983) P-Value
Age at Baseline 41.7 (35.4, 47.3) 42.9 (38.3, 48.6) 42.1 (35.7, 47.4) 0.07
Education 15 (13, 16) 16 (13, 17) 15 (13, 16) 0.25
UHDRS Motor Score 1 (0, 3) 1 (0, 4) 1 (0, 3) 0.79
UHDRS Chorea Score 0 (0,0) 0 (0,0) 0 (0,0) 0.0527
Beck Depression Score 3 (1,6) 3 (1,6) 3 (1,6) 0.32
UHDRS Behavioral Score (Frequency × Severity) 4 (0, 10) 6 (2, 13) 4 (0, 10) 0.0127
Female Gender 608 (69%) 73 (72%) 681 (69%) 0.49
CAG ≥ 37 295 (33%) 50 (50%) 345 (35%) 0.0014
Married 573 (70%) 65 (70%) 638 (70%) 0.98
Values shown are medians (25%, 75% percentiles) or N (%), as appropriate.P-values indicate the significance levels for comparisons by genetic 
testing status using Kruskal-Wallis tests or chi-square tests, as appropriate.
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Table 2
Baseline Characteristics to Predict Time to Genetic Testing (N = 983)
Hazard Ratios, Individual Models Hazard Ratios, Combined Model
HR (95% CI) P-Value HR (95% CI) P-Value
CAG ≥ 37 2.04 (1.38, 3.02) 0.0004 1.91 (1.28, 2.85) 0.0015
UHDRS Motor Score 1.03 (0.98, 1.08) 0.31 --- ---
UHDRS Chorea Score 1.12 (0.98, 1.28) 0.10 --- ---
Beck Depression Score 1.03 (0.99, 1.06) 0.16 --- ---
UHDRS Behavioral Score (Frequency × Severity) 1.03 (1.01, 1.04) 0.0046 1.02 (1.00, 1.04) 0.0250
Values shown are hazard ratios (95% confidence intervals) from Cox proportional hazards models. The hazard ratios are per point of the scale; for 
example, a motor score hazard ratio of 1.03 means that, for each one point increase in the motor score, the chance of getting tested increased by 
3%. All models were adjusted for age and gender. The combined model includes only those measures that were significant in the individual models.
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Table 3
Characteristics of Tested Subjects by CAG Status (N = 87)
CAG <37 (N = 47) CAG ≥37 (N = 40) P-Value
SCORES AT PRIOR VISIT
 UHDRS Motor Score 0 (0, 3) 3 (0, 12) 0.0009
 UHDRS Chorea Score 0 (0, 0) 1 (0, 4) 0.0005
 Beck Depression Score 3 (1, 8) 5 (1, 13) 0.71
 UHDRS Behavioral Score (Frequency × Severity) 3 (0, 10) 5.5 (2, 19.5) 0.07
SCORES AT VISIT WHEN TESTING WAS DISCLOSED
 UHDRS Motor Score 1 (0, 2) 5 (2, 14.5) <0.0001
 UHDRS Chorea Score 0 (0, 0) 0 (0, 3.5) 0.0016
 Beck Depression Score 3 (0, 5) 3 (1, 10.5) 0.12
 UHDRS Behavioral Score (Frequency × Severity) 2 (0, 6) 7 (0, 13) 0.0379
CHANGES FROM PRIOR VISIT
 Change in UHDRS Motor Score 0 (0, 0) 0 (-1, 4) 0.0016
 Change in UHDRS Chorea Score 0 (0, 0) 0 (0, 1) 0.17
 Change in Beck Depression Score -1 (-3, 0) 0 (-2, 3) 0.0286
 Change in UHDRS Behavioral Score (Frequency × Severity) 0 (-4, 2) -0.5 (-6, 2.5) 0.31
Values shown are medians (25%, 75% percentiles). P-values indicate the significance levels for comparisons by CAG status using Kruskal-Wallis 
tests for the scores at each visit, and analysis of covariance on the ranks, including the prior visit score, was used for the change scores.
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